Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Satsuma
1337 3rd Avenue
San Francisco, CA 94122
Phone: 415-505-0809
http://www.satsumarx.com/

Satsuma Pharmaceuticals' lead product candidate is STS101, a potential best-in-class therapy for migraine that combines the gold-standard anti-migraine drug, dihydroergotamine (DHE), with unique and proprietary dry-powder nasal formulation and delivery technologies created and developed over the past 15 years by SNBL that enable rapid absorption with high bioavailability of drugs delivered via the nose. DHE has multiple therapeutic advantages over other migraine therapies, including triptan therapies, but is not currently available in a fast-acting, patient-friendly, non-injectable preparation that achieves a pharmacokinetic profile similar to that achieved with injection.

Key Contact
Name
John Kollins
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
01/09/17 $12,000,000 Series A RA Capital Management
TPG Biotech
undisclosed


Featured Reading